Imexpharm (STC:IMP) Other Stockholders Equity: ₫130,116 Mil (As of Mar. 2026)


STC:IMP Imexpharm Corp STC:IMP
98 GF Score
Price ₫41,200.00
GF Value ₫51,983.47
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Imexpharm Other Stockholders Equity?

Imexpharm STC:IMP -0.36% 98 Other Stockholders Equity is ₫130,116 Mil as of Mar. 2026. GuruFocus rates STC:IMP with a GF Score™ of 98/100 and a GF Value™ of ₫51,983.47 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Imexpharm's Other Stockholders Equity for the quarter that ended in Mar. 2026 was ₫130,116 Mil.

Imexpharm's quarterly Other Stockholders Equity increased from Sep. 2025 (₫130,116 Mil) to Dec. 2025 (₫130,116 Mil) but then declined from Dec. 2025 (₫130,116 Mil) to Mar. 2026 (₫130,116 Mil).

Imexpharm's annual Other Stockholders Equity declined from Dec. 2023 (₫437,089 Mil) to Dec. 2024 (₫134,919 Mil) and declined from Dec. 2024 (₫134,919 Mil) to Dec. 2025 (₫130,116 Mil).

Imexpharm Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Imexpharm's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Imexpharm Other Stockholders Equity Chart

Imexpharm Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 422,922.34 455,738.38 437,089.47 134,919.32 130,116.31

Imexpharm Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 134,919.32 134,919.32 130,116.31 130,116.31 130,116.31
STC:IMP
98GF Score
Imexpharm Corp STC:IMP
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Imexpharm Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of ₫130,116 Mil mean?
Imexpharm (STC:IMP) has a Other Stockholders Equity of ₫130,116 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Imexpharm and its competitors.
Is Imexpharm's Other Stockholders Equity too high?
Imexpharm's current Other Stockholders Equity is ₫130,116 Mil. Overall, Imexpharm has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Imexpharm's Other Stockholders Equity compare to ZTS and UTHR?
Imexpharm's Other Stockholders Equity of ₫130,116 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Imexpharm and its competitors. Imexpharm's current Other Stockholders Equity is ₫130,116 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imexpharm stock overvalued right now?
Based on GuruFocus' analysis, Imexpharm (STC:IMP) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫51,983.47, compared to a current price of ₫41,200.00 — trading 20.7% below its estimated fair value. The current Other Stockholders Equity is ₫130,116 Mil. Imexpharm's overall GF Score™ is 98/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Imexpharm (STC:IMP), the current Other Stockholders Equity is ₫130,116 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Imexpharm (STC:IMP) Overvalued in 2026?

Based on GuruFocus' analysis, Imexpharm stock appears to be undervalued. The current stock price of ₫41,200.00 is trading 20.7% below its estimated GF Value™ of ₫51,983.47. GuruFocus considers Imexpharm to be Modestly Undervalued.

Key valuation signals for STC:IMP:

  • Other Stockholders Equity: ₫130,116 Mil
  • GF Value™: ₫51,983.47 vs. price of ₫41,200.00 (20.7% below fair value)
  • GF Score™: 98/100 with 2 warning signs

No single metric tells the full story. See the STC:IMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Imexpharm Business Description

Address 4 Road 30/04 Street Ward 1, Cao Lanh City, Dongthap, VNM
Imexpharm Corp is engaged in the manufacture, import, export, and trade of pharmaceuticals and medicinal chemical products. The company's products include oral and injective antibiotic, digestion, central nervous system, cardiovascular, diabetes, musculoskeletal system, respiratory system, analgesic-anti-inflammatory, anti-allergy, ophthalmology, external drugs, and anti-parasitic, as well as vitamins and minerals.
98GF Score

Get the complete analysis for STC:IMP

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₫41,200.00
Price
₫51,983.47
GF Value